Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...
Equillium Reports Positive Phase 2 Results for Itolizumab in Ulcerative Colitis, Shares Surge
Though the baseline illness severity was uneven, with more severe patients in the itolizumab arm, the medication showed great ...
Equillium announces itolizumab study achieves secondary endpoint
Equillium (EQ) and Biocon announced topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ...
The American Journal of Managed Care13h
Mirikizumab Demonstrates Superior Maintenance Efficacy in UC Treatment
Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...
AI tool helps find life-saving medicine for rare disease
After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a ...
Equillium stock rallies 26% on itolizumab study data
Shares of Equillium (NASDAQ:EQ) soared 26% Thursday after the company and partner Biocon reported positive topline results from a Phase 2 study of the drug itolizumab in the treatment of moderate to ...
American Association of Individual Investors1d
Which Is a Better Investment, Biogen Inc. or Gilead Sciences, Inc. Stock?
Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.